An evidence based review of Dupilumab in the treatment of moderate to severe asthma
Current Therapeutic Research(2019)
摘要
•Dupilumab can reduce the risk of severe asthma exacerbations.•FEV1 values were improved with dupilumab treated groups when compared to placebo-treated groups.•Safety outcomes of dupilumab and placebo treated groups were compared and showed greater prevalence of injection site reaction in dupulimab treated group.•Future studies need to be focused on the concerns like the use of dupilumab in vulnerable population, evaluation of long term use and comparison of efficacy with other biologics which may facilitate wider acceptance globally.
更多查看译文
关键词
asthma,dupilumab,interleukins,monoclonal antibodies,systematic review
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要